Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
Primary objective:
To evaluate safety and tolerability, adverse events (AEs), vital signs, ECG, bleeding time,
evaluation of antibody titer and safety laboratory tests
Secondary objectives:
To evaluate the pharmacokinetics and pharmacodynamics (platelet aggregation)of six ascending
single intravenous doses of PR-15 in healthy volunteers